The new coronavirus is more heat-resistant than SARS, and researchers have found a way to kill the virus completely. Oxford University is currently conducting the largest covid-19 vaccine trial. Who warns that there is no evidence that antibodies to the new coronavirus can provide long-term immunity.
The new coronavirus is more heat resistant, and researchers have found ways to kill the virus completely
A new study has found a way to kill the new coronavirus faster, pointing out that the new coronavirus is more heat resistant than previously thought. The study was published in biorxiv but has not been peer-reviewed. Researchers from France infected African green monkey kidney cells with the new coronavirus, placing them in "dirty" and "clean" environments, the study said. When two vials were heated at 140 degrees Fahrenheit (60 degrees Celsius) for an hour, the researchers found that the virus could still replicate. Higher temperature and shorter time can effectively terminate the replication ability of virus. The researchers pointed out that the scheme of heating at 92 ℃ for 15 minutes is better than that of heating at 56 ℃ for 30 minutes and 60 ℃ for 60 minutes, which can kill the virus quickly and effectively. The researchers conducted the study to help scientists develop safe treatments around the world, while continuing to find treatments and vaccines for covid-19. The researchers said that although the scheme of heating at 92 ℃ for 15 minutes can kill the new coronavirus, it may also fragment its RNA, thus affecting detection. Since novel coronavirus pneumonia samples are usually collected in the BSL-2 laboratory, the results of this study will help to select the most suitable inactivation plan to prevent laboratory personnel exposed to the new crown virus directly and indirectly.
Oxford University is currently conducting the largest covid-19 vaccine trial
Oxford University is currently carrying out the largest covid-19 vaccine test. By the middle of next month, more than 500 volunteers will actively participate in the test, including representative samples aged 18-55, for large-scale randomized early and mid-term clinical trials of its potential vaccine. The vaccine uses a harmless, modified virus to trigger an immune response, and this immune response The novel coronavirus should also be effective. The trial will divide a total of 510 subjects into five groups, one of which will receive follow-up booster injections after the original vaccination. The technology behind the vaccine has been used to develop about 10 other treatments, but one will need to be adopted, including the establishment of different test groups in different countries to ensure representative results, because the infection rate of different preventive measures varies greatly in different countries. The team behind the vaccine is also seeking additional funding to help scale-up production, as its goal is to start mass production six months after human trials on the premise that potential vaccines prove effective. In the final phase of the trial, the target population is 5000, and it is possible to start to provide some doses for front-line medical staff before September. The Oxford trial is one of the few vaccine tests to enter human trials, but more are coming online. Moderna and inovio are currently conducting clinical human trials in the United States, and they also say they plan to put the vaccine into emergency use earlier after preliminary clinical results are available. Even if some of the candidate vaccines prove to be effective and there is a certain supply by autumn, that doesn't mean they will be widely used. This still requires further testing and scaling up production, as well as distribution and management, all of which will add months of work. However, the unprecedented nature of the covid-19 pandemic has led to a significant increase in the efficiency of the development process.
Who warning: there is no evidence that new coronavirus antibodies can be used for long-term immunization
Novel coronavirus pneumonia and asymptomatic infections in blood with new crown virus antibodies in the blood were found to have long-term immunity against the new crown virus, a warning was issued at a news conference on 17 local time. Officials say it is not certain that people with antibodies will be adequately protected from further illness.
According to Forbes news and CNBC, who experts said that serum test of new coronavirus (also known as antibody test) can really show whether a person has been infected with the virus in the past, but there is no evidence that the test can prove whether a person has immunity or no longer has the risk of reinfection. "There is no evidence that using serological tests can prove whether a person is immune or immune from reinfection," said Dr Maria van Khov of who Dr Mike Ryan, who's executive director of the emergency plan, said scientists were still determining how long antibodies might provide protection to people infected with the new coronavirus. "No one can be sure that people with antibodies are adequately protected from further illness or exposure to the virus. In addition, some tests have sensitivity problems, and they may give false negative results. " Novel coronavirus pneumonia is a test of serum antibody or antibody detection. Novel coronavirus pneumonia patients had antibodies against two infections earlier this week, which led to concerns that patients might not be immune after recovery. "I don't think we have an answer to the question of reinfection after recovery. This is an unknown number. "
Science Science
Understand the unknown and open cognition
Pay attention to the Chinese official account.
Science Science English platform
THE SCIENCE OF EVERYTHING
English official account
TechEdge
Technology brightens the future
Pay attention to the Chinese official account.
⚪ suddenly, please give me a tax
Share "ticket circle", pass every exam, lighten "watching" SCI employment rate increased by 18%